Allogeneic peripheral blood stem cell transplantation in aplastic anemia [7]

Indian Pediatrics

Volumn 43, Issue 1, 2006, Pages 82-83

  Damodar, Sharat ^a   Murthy, Sreedhar ^a  

^a Narayana Health City   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYCLOSPORIN A; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; MEROPENEM; TEICOPLANIN; THYMOCYTE ANTIBODY;

ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; APLASTIC ANEMIA; CASE REPORT; DOSE RESPONSE; GRAFT VERSUS HOST REACTION; HUMAN; LETTER; MALE; POSTOPERATIVE COMPLICATION; PROPHYLAXIS; SCHOOL CHILD; TREATMENT OUTCOME;

ANEMIA, APLASTIC; CHILD; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HUMANS; MALE; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 32644435814     PISSN: 00196061     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (5)

1. Bacigalupo A, Brand R, Oneto R, Bruno B, Socie G, Passweg J, et al. Treatment of acquired severe aplastic anemia: bone marrow transplantation compared with immunosuppressive therapy. The European group for Blood and Marrow Transplantation experience. Semin Hematol 2000; 37: 69-80.
2. Horowitz MM. Current status of allogenic bone marrow transplantation in acquired aplastic anemia. Semin Hematol 2000; 37: 30-42.
3. Stucki A, Leisenring W, Sandmaier BM, Sanders J, Anasetti C, Storb R. Decreased rejection and improved survival of first and second marrow transplant for severe aplastic anemia (a 26-year retrospective analysis). Blood 1998; 92: 2742-2749.
4. Deeg HJ, Leisenring W, Storb R, Nims J, Flowers ME, Witherspoon RP, et al. Longterm outcome after marrow transplantation for severe aplastic anemia. Blood 1998; 91: 3637-3645.
5. Dulley FL, Vigorito AC, Aranha FJ, Sturaro D, Ruiz MA, Saboya R, et al. Addition of low dose cyclophosphamide in aplastic anemia patients prior to allogeneic bone marrow transplantation to reduce rejection. Bone Marrow Transplant 2004; 33: 9-13.